News
Pharmacelera Summary 2020
By Enric Gibert – Jan. 11, 2021 No doubt that 2020 was a challenging year. We sincerely hope you, your colleagues, and
December 28, 2020
No Comments
By Enric Gibert – Jan. 11, 2021 No doubt that 2020 was a challenging year. We sincerely hope you, your colleagues, and
By Giorgia Zaetta – Dec. 11, 2020 Lipophilicity is the property of a molecule that describes its distribution between water and octanol,
By Melanie Berg – Nov. 30, 2020 Pharmacelera is proud to announce today, that an agreement was reached with Helmholtz Centre for
By Lluis Campos – Sep. 23, 2020 Molecular Docking is a key tool in Structure Based Drug Discovery (SBDD), as it aims
We are happy to announce that PharmScreen, our virtual screening tool is available for Knime. Knime is a free open-source platform that
The Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) or COVID-19 has spread to all countries without exception, affecting not only risk-population but
2019 was an exciting year for Pharmacelera and we look forward to 2020 with energy and commitment. Stay tuned for updates in
By Javier Vazquez – Dec. 11, 2019 Virtual Screening (VS) is a core in-silico technology in medicinal and computational chemistry. Several tools
Researchers at Bellvitge Biomedical Research Institute will develop a research project with the company Pharmacelera to look for new molecules that block
PharmScreen evolves day by day thanks to the feedback of many computational and medicinal chemists! We have been incorporating different features to
Why protein-protein interactions are important? Protein-protein interactions (PPI) play a major role in several of the cellular functions and processes that take
Today, the amount of data generated in many fields such as engineering, social sciences or medicine is suffering a tremendous scale-up. Extraction
CCDC and Pharmacelera combine virtual screening and machine learning expertise to help scientists accelerate drug discovery Barcelona and Cambridge, UK, 26th June 2019. The
The Universitat Autònoma de Barcelona (UAB) and Pharmacelera have reached an agreement to perform a research project in the area of Parkinson
Last December, Biocat 1 reported that the Bioregion of Catalonia is witnessing a growth in international investment and described Catalonia as a dynamic
Pharmacelera has been awarded an SME Phase I grant from the European Commission for its MolPredict project. The EU received 2009 requests